A digest of the evidence-based Clinical Practice Guideline for Rapidly Progressive Glomerulonephritis 2020.

Maintenance therapy (remission maintenance therapy for treating vasculitis): approximately 3-6 months after treatment initiation and after confirming that the symptoms of vasculitis, such as progression of renal failure, have disappeared. Treatment of anti-GBM antibody nephritis Patients with anti-GBM antibody nephritis have the worst renal prognosis among patients with RPGN; survival rate is very poor in the presence of pulmonary hemorrhage. Grades of recommendations: "We recommend" "We suggest" None Definition of disease Rapidly progressive glomerulonephritis (RPGN) is defined in Japan as "a syndrome that rapidly progresses to renal failure within a few weeks or months and is accompanied by urinary findings of nephritis." Diagnosis Differential diagnosis RPGN is a clinical syndrome that is classified based on its manifestations: primary RPGN, which only damages the kidneys, or secondary RPGN, which occurs in association with other systemic disorders and infections. [Extracted from the article]